Shots:

• Atara to receive $60M upfront and ~$610M as development- regulatory & commercialization milestones + tiered royalties on net sales. The collaboration focuses on off-the-shelf T-cell immunotherapy ATA3271 and ATA2271
• Atara will lead to IND and process development for ATA3271 and will continue to be responsible for P-I study of ATA2271 while Bayer will be responsible for submitting the IND and subsequent clinical development and commercialization
• Atara will also provide translational & clinical manufacturing services to be reimbursed by Bayer. In addition- for a limited period- Bayer has a non-exclusive right to negotiate a license for additional Atara CAR T product candidates

 ­ Ref: Businesswire | Image: Express Pharma